GlaxoSmithKline (NYSE: GSK) will likely be kicking itself for returning its co-commercialization rights to the drug back to Amicus last year, and for selling its equity stake in Amicus this past October. Sanofi's Fabrazyme, an ultra-pricey twice-weekly injection that costs patients around $200,000 per year. Who will make a run at this company first.
I'm hoping for lower pps.
Naked shorting, stealing your money, hope you guys didn't didn't sell out to quick.
Good stocks can get boring, No volitility. Then out of the blue move up quickly. Can't time this one, just hold and add all the way up.
See you all at 30. Enjoy the ride.
We should be heading back up to the 52 week highs at a good pace, glta.
Then a massive run up, will be patient this time, glta !
This is a game changer, linking in to the brain, much more to come.
Better late then never.